CN112939850B - 一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法 - Google Patents

一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法 Download PDF

Info

Publication number
CN112939850B
CN112939850B CN202110092900.3A CN202110092900A CN112939850B CN 112939850 B CN112939850 B CN 112939850B CN 202110092900 A CN202110092900 A CN 202110092900A CN 112939850 B CN112939850 B CN 112939850B
Authority
CN
China
Prior art keywords
aldehyde
acetonitrile
reaction
arylboronic acid
ring structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110092900.3A
Other languages
English (en)
Other versions
CN112939850A (zh
Inventor
包永胜
白朝鲁门
刘丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Normal University
Original Assignee
Inner Mongolia Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Normal University filed Critical Inner Mongolia Normal University
Priority to CN202110092900.3A priority Critical patent/CN112939850B/zh
Publication of CN112939850A publication Critical patent/CN112939850A/zh
Application granted granted Critical
Publication of CN112939850B publication Critical patent/CN112939850B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/08Preparation by ring-closure
    • C07D213/09Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/08Preparation by ring-closure
    • C07D213/09Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles
    • C07D213/12Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from unsaturated compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/0825Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/083Syntheses without formation of a Si-C bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明公开了一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法,包括如下步骤,将将钯催化剂、醛、芳基硼酸、配体和氧化剂溶解于乙腈中,在回流条件下,搅拌24‑72小时,得到混合液;过滤混合液,浓缩滤液,经柱层析,得到多取代吡啶。本发明方法反应物均无需过量,原料利用率较高,反应在中性条件下进行,反应物分子和产物分子中的官能团不受影响,尤其适合制备利用传统缩合反应相对较难制备的多取代吡啶,反应条件温和,操作简单,原子经济型高,适于在工业生产中应用。

Description

一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的 方法
技术领域
本发明涉及一种合成吡啶环结构的方法,具体涉及一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法,属于吡啶类化合物制备技术领域。
背景技术
吡啶环作为一种基本的结构单元,存在于多种天然产物,药物前体,功能材料中,被广泛应用于农药、医药、染料、化学试剂、和精细化工产品中。传统的合成吡啶环的方法一般是将羰基化合物与胺类物质缩合,包括芳香醛、芳香酮、醋酸铵的缩合,苄胺与芳香酮的缩合等。但由于反应过程中存在反应条件苛刻、产率低等缺点,因此不符合可持续发展的需求。近年来,化学家们越来越倾向于温和条件下过渡金属催化的方法来合成吡啶环,以便增加合成产率及底物普适性。例如过渡金属催化的[2+2+2]或[4+2]腈与烯烃的环加成反应,过渡金属催化的肟醚与芳香醛、二甲基甲酰胺、二甲基胺等的加成反应等。由于腈类可以与多种有机物发生碳钯化反应制备芳香酮,所以近两年有人报道了通过腈类的碳钯化反应合成吡啶环的方法。但是,这些反应必须用二腈类、δ-酮基腈类、拉电子基团取代的腈类做底物,直接利用脂肪腈的碳钯化反应制备吡啶环的反应还未见报道。
发明内容
本发明提供了一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法,可以在温和条件下高效地制备各种吡啶衍生物。
本发明方法主要采用脂肪腈类的碳钯化反应及串联缩合反应制备多种吡啶衍生物,反应中脂肪腈作为C4N1供体、醛作为C1供体共同构建吡啶环,打破脂肪腈不能通过碳钯化反应直接制备吡啶环的技术壁垒。
由于脂肪腈的碳钯化反应可以产生亚胺中间体及酮,因此,脂肪腈既作为酮源,也作为氮源,通过与醛的缩合反应可以制备吡啶环结构。
本发明方法所涉及的化学反应方程式如下:
Figure BDA0002913353120000011
利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法,包括如下步骤:
(1)将钯催化剂、醛、芳基硼酸、配体和氧化剂溶解于乙腈中得到混合液A;作为优选,所述醛、钯催化剂、配体、芳基硼酸、氧化剂的摩尔比为1:0.02~0.5:0.04-0.5:2-4:1-3。
所述的醛为RCHO,其中R为
Figure BDA0002913353120000012
/>
Figure BDA0002913353120000013
Figure BDA0002913353120000021
(n=1,2,3,4,5,6);
所述的钯催化剂为醋酸钯、三氟乙酸钯、氯化钯、四三苯基膦钯或负载纳米钯催化剂(Pd/Al2O3,Pd/C,Pd/MOF-5);
所述的配体为
Figure BDA0002913353120000022
Figure BDA0002913353120000023
所述的芳基硼酸为ArB(OH)2,其中Ar为
Figure BDA0002913353120000024
Figure BDA0002913353120000025
(n=1,2,3,4,5),/>
Figure BDA0002913353120000026
Figure BDA0002913353120000027
所述的氧化剂为AgCO3,AgTFA,Cu(OAc)2,
Figure BDA0002913353120000028
Figure BDA0002913353120000029
(2)将混合液A在回流条件下,搅拌24-72小时,得到混合液B;
依据所用原料种类的不同,所述的回流条件可对应不同的温度;步骤(2)中的反应,其反应时间并没有严格的限制,通过定时取样,用薄层色谱法(TLC)等现有手段进行跟踪分析,当其中一种原料或多种原料都反应完毕,视为反应的终点即可。
(3)过滤混合液B,浓缩滤液,经柱层析,得到多种取代吡啶。
与现有技术相比,本发明具有如下有益效果:
本发明方法通过醛、芳基硼酸、乙腈的串联反应制备吡啶环结构,反应物均无需大大过量。与原有技术相比,无需活化的腈类作为反应底物,直接利用工业商品乙腈进行碳钯化反应,减少了预活化的反应步骤,实现一锅法合成吡啶衍生物。反应中乙腈即作为C4N1供体又作为溶剂,原料利用率较高,具有极高的原子经济性。反应在中性条件下进行,反应物分子和产物分子中的官能团不受影响,尤其适合制备利用传统缩合反应相对较难制备的多取代吡啶。反应条件温和,反应温度低于100℃,操作简单,产率较高,适用于在工业生产中应用。
具体实施方式
实施例1
本实施例通过苯甲醛、苯硼酸与乙腈的串联反应制备2,4,6-三苯基吡啶。
将0.5mmol苯甲醛、0.05mmol醋酸钯、0.1mmol联吡啶、1.0mmol苯硼酸与1mmolAgTFA溶解于2mL乙腈中,将得到的反应混合液回流36小时;过滤所得到的混合液,浓缩滤液,经柱层析,即可得到2,4,6-三苯基吡啶,产率约为51%。
核磁监测数据如下:1H NMR(600MHz,CDCl3)δ8.24–8.17(m,4H),7.88(s,2H),7.76–7.70(m,2H),7.54–7.48(m,6H),7.48–7.42(m,3H);13C NMR(151MHz,CDCl3)δ157.5,150.3,139.6,139.1,129.2,129.1,129.0,128.8,127.2,127.2,117.2.
实施例2
本实施例通过苯甲醛、苯硼酸与乙腈的串联反应制备2,4,6-三苯基吡啶。
将0.5mmol苯甲醛、50mg 3wt%Pd/Al2O3、0.1mmol的1,10-菲罗啉、1.5mmol苯硼酸与1mmol
Figure BDA0002913353120000031
溶解于2mL乙腈中,将得到的反应混合液回流48小时;过滤所得到的混合液,浓缩滤液,经柱层析,即可得到2,4,6-三苯基吡啶,产率约为64%。
核磁监测数据如下:1H NMR(600MHz,CDCl3)δ8.24–8.17(m,4H),7.88(s,2H),7.76–7.70(m,2H),7.54–7.48(m,6H),7.48–7.42(m,3H);13C NMR(151MHz,CDCl3)δ157.5,150.3,139.6,139.1,129.2,129.1,129.0,128.8,127.2,127.2,117.2.
实施例3
本实施例通过邻甲基苯甲醛、苯硼酸与乙腈的串联反应制备2,6-二苯基-4-邻甲基苯基吡啶。
将0.5mmol邻甲基苯甲醛、0.05mmol醋酸钯、0.1mmol的联吡啶、1.5mmol苯硼酸与1mmol
Figure BDA0002913353120000032
溶解于2mL乙腈中,将得到的反应混合液回流48小时;过滤所得到的混合液,浓缩滤液,经柱层析,即可得到2,6-二苯基-4-邻甲基苯基吡啶,产率约为79%。
核磁监测数据如下:1H NMR(600MHz,CDCl3)δ8.18(d,J=7.7Hz,4H),7.67(s,2H),7.51(t,J=7.5Hz,4H),7.44(t,J=7.3Hz,2H),7.38-7.29(m,4H),2.37(s,3H);13C NMR(151MHz,CDCl3)δ156.8,151.6,139.8,139.3,135.2,130.7,129.3,129.1,128.7,128.4,127.2,126.2,119.5,20.4.
实施例4~12
实施例4~12中均利用实施例3的反应条件以及物料配比,仅改变醛以及芳基硼酸的种类,各实施例中所用的芳基酯和所得到的产物及产物收率参见表1。
表1
Figure BDA0002913353120000033
/>
Figure BDA0002913353120000041
实施例4~12中目标产物的核磁监测数据如下:
实施例4:2,6-二苯基-4-对甲基苯基吡啶
Figure BDA0002913353120000042
1H NMR(600MHz,CDCl3)δ8.20(d,J=7.4Hz,4H),7.88(s,2H),7.66(d,J=8.0Hz,2H),7.51(t,J=7.6Hz,4H),7.44(t,J=7.3Hz,2H),7.33(d,J=7.9Hz,2H),2.44(s,3H);13CNMR(151MHz,CDCl3)δ157.5,150.1,139.6,139.1,136.1,129.9,129.0,128.7,127.2,127.0,117.0,21.3.
实施例5:2,6-二苯基-4-对甲氧基苯基吡啶
Figure BDA0002913353120000051
1H NMR(600MHz,CDCl3)δ8.20(d,J=7.3Hz,4H),7.86(s,2H),7.71(d,J=8.7Hz,2H),7.51(t,J=7.6Hz,4H),7.44(t,J=7.3Hz,2H),7.05(d,J=8.7Hz,2H),3.88(s,3H);13CNMR(151MHz,CDCl3)δ160.5,157.5,149.7,139.6,131.3,129.0,128.7,128.4,127.2,116.7,114.6,55.5.
实施例6:2,6-二苯基-4-邻氯苯基吡啶
Figure BDA0002913353120000052
1H NMR(600MHz,CDCl3)δ8.19(d,J=7.4Hz,4H),7.78(s,2H),7.56-7.54(m,1H),7.51(t,J=7.6Hz,4H),7.46-7.42(m,3H),7.41-7.37(m,2H);13C NMR(151MHz,CDCl3)δ156.9,148.7,139.3,138.5,132.3,130.9,130.3,129.7,129.1,128.7,127.2,127.2,119.5.
实施例7:2,6-二苯基-4-对硝基苯基吡啶
Figure BDA0002913353120000053
1H NMR(600MHz,CDCl3)δ8.39(d,J=8.7Hz,2H),8.21(d,J=7.4Hz,4H),7.90(d,J=8.7Hz,2H),7.88(s,2H),7.53(t,J=7.5Hz,4H),7.48(t,J=7.2Hz,2H);13C NMR(151MHz,CDCl3)δ158.0,148.2,147.9,145.5,139.0,129.5,128.9,128.2,127.2,124.4,117.0.
实施例8:2,6-二苯基-4-(2-甲基-4-氟苯基)吡啶
Figure BDA0002913353120000054
1H NMR(600MHz,CDCl3)δ8.20–8.15(m,4H),7.62(s,2H),7.52–7.48(m,4H),7.46–7.42(m,2H),7.28(dd,J=8.4,5.9Hz,1H),7.04(dd,J=9.7,2.5Hz,1H),7.03–6.99(m,1H),2.35(s,3H);13C NMR(151MHz,CDCl3)δ162.6(d,J=247.2Hz,1C),156.9,150.5,139.3,137.8(d,J=8.0Hz,1C),135.8(d,J=3.1Hz,1C),130.9(d,J=8.4Hz,1C),129.2,128.8,127.1,119.5,117.3(d,J=21.2Hz,1C),113.1(d,J=21.2Hz,1C),20.6(d,J=1.3Hz,1C).
实施例9:2,6-二苯基-4-(2-噻吩)吡啶
Figure BDA0002913353120000055
1H NMR(600MHz,CDCl3)δ8.21–8.15(m,4H),7.86(s,2H),7.62–7.60(m,1H),7.52(t,J=7.6Hz,4H),7.47–7.43(m,3H),7.17(dd,J=4.9,3.7Hz,1H);13C NMR(151MHz,CDCl3)δ157.7,143.1,141.9,139.3,129.2,128.7,128.4,127.2,127.0,125.3,115.4.
实施例10:2,6-二-(4-甲基苯基)-4-苯基吡啶
Figure BDA0002913353120000061
1H NMR(600MHz,CDCl3)δ8.10(d,J=8.1Hz,4H),7.83(s,2H),7.74(d,J=7.3Hz,2H),7.52(dd,J=9.6,5.4Hz,2H),7.46(t,J=7.3Hz,1H),7.31(d,J=7.9Hz,4H),2.43(s,6H);13C NMR(151MHz,CDCl3)δ157.4,150.1,139.3,139.0,136.8,129.4,129.1,128.9,127.2,127.1,116.6,21.4.
实施例11:2,6-二-(4-三甲基硅基苯基)-4-苯基吡啶
Figure BDA0002913353120000062
1H NMR(600MHz,CDCl3)δ8.17(d,J=8.0Hz,4H),7.89(s,2H),7.75(d,J=7.2Hz,2H),7.67(d,J=7.9Hz,4H),7.54(t,J=7.5Hz,2H),7.48(t,J=7.3Hz,1H),0.32(s,18H);13C NMR(151MHz,CDCl3)δ158.7,151.4,142.7,140.8,140.1,134.8,130.3,130.2,128.3,127.6,118.5.
实施例12:2,6-二-(4-三氟甲氧基苯基)-4-苯基吡啶
Figure BDA0002913353120000063
1H NMR(600MHz,CDCl3)δ8.20(d,J=8.1Hz,4H),7.86(s,2H),7.72(d,J=7.5Hz,2H),7.54(t,J=7.4Hz,2H),7.51-7.47(m,1H),7.35(d,J=8.2Hz,4H);13C NMR(151MHz,CDCl3)δ156.3,150.8,150.1,138.6,137.9,129.3,129.3,128.6,127.2,121.1,120.5(q,J=257.5Hz,1C),117.4.

Claims (4)

1.一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法,其特征在于:包括如下步骤:
S1将钯催化剂、醛、芳基硼酸、配体和氧化剂溶解于乙腈中得到混合液A;
所述的醛为RCHO,其中R为
Figure FDA0004175037370000011
Figure FDA0004175037370000012
所述的钯催化剂为醋酸钯或Pd/Al2O3
所述的配体为
Figure FDA0004175037370000013
所述的芳基硼酸为ArB(OH)2,其中Ar为
Figure FDA0004175037370000014
(n=1,2,3,4,5),
Figure FDA0004175037370000015
Figure FDA0004175037370000016
所述的氧化剂为AgTFA,
Figure FDA0004175037370000017
S2将混合液A在回流条件下,搅拌24-72小时,得到混合液B;
S3过滤混合液B,浓缩滤液,经柱层析,得到多种取代吡啶。
2.根据权利要求1所述的利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法,其特征在于:所述的醛与钯催化剂的摩尔比为1:0.02~0.5。
3.根据权利要求1所述的利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法,其特征在于:所述的醛与芳基硼酸的摩尔比为1:2~4。
4.根据权利要求1所述的利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法,其特征在于:所述的醛与氧化剂的摩尔比为1:1~3。
CN202110092900.3A 2021-01-25 2021-01-25 一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法 Active CN112939850B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110092900.3A CN112939850B (zh) 2021-01-25 2021-01-25 一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110092900.3A CN112939850B (zh) 2021-01-25 2021-01-25 一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法

Publications (2)

Publication Number Publication Date
CN112939850A CN112939850A (zh) 2021-06-11
CN112939850B true CN112939850B (zh) 2023-05-26

Family

ID=76236181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110092900.3A Active CN112939850B (zh) 2021-01-25 2021-01-25 一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法

Country Status (1)

Country Link
CN (1) CN112939850B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617258A (zh) * 2012-03-12 2012-08-01 浙江大学 一种利用吡啶甲酸酯与醛的酯交换反应制备酯的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB589625A (en) * 1944-01-19 1947-06-25 Chem Ind Basel Manufacture of new pyridine and piperidine compounds
WO2002057273A1 (en) * 2001-01-20 2002-07-25 Trigen Limited Serine protease inhibitors comprising a hydrogen-bond acceptor
US7449601B2 (en) * 2004-12-16 2008-11-11 E. I. Du Pont De Nemours And Company Catalysts useful for catalyzing the coupling of arylhalides with arylboronic acids
CN107474047B (zh) * 2017-08-29 2019-10-29 浙江工业大学 1,2,4-三唑并杂环类化合物的合成方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617258A (zh) * 2012-03-12 2012-08-01 浙江大学 一种利用吡啶甲酸酯与醛的酯交换反应制备酯的方法

Also Published As

Publication number Publication date
CN112939850A (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
EP0916637B1 (en) Process for preparating optically active compounds
CN108409747B (zh) 一种2-氨基喹啉并二氢呋喃类化合物的合成方法
EP1806336A1 (en) Titanium compound and method for producing optically active cyanohydrins
CN110294689B (zh) 一种钌金属配合物催化伯胺脱氢制备腈类化合物的方法
Francos et al. Synthesis and catalytic applications of ruthenium (ii)–phosphino-oxime complexes
CN112939850B (zh) 一种利用醛、芳基硼酸、乙腈的串联反应合成吡啶环结构的方法
CN112375105B (zh) 一种n,n-配位的含间位碳硼烷配体的二价镍配合物的应用
CN109096174A (zh) 一种n-烃基-2,5-未取代的[60]富勒烯吡咯烷衍生物的合成方法
CN107501338B (zh) 一种2,6-二氨基吡啶缩4-羧基苯甲醛双希夫碱钴配合物的制备方法
CN110922431B (zh) 两种氮杂环卡宾钯金属配合物的合成方法及其应用
US8729303B2 (en) 2,2′,6,6′-tetrasubstituted aminophosphine ligand and its synthesis method
CN107513078B (zh) 一种2,6-二氨基吡啶缩3-羧基苯甲醛双希夫碱钴配合物的制备方法
CN112778351A (zh) β-二甲基苯基硅取代芳香硝基化合物的制备方法
CN113735826B (zh) 一种3-亚苄基-2,3-二氢喹诺酮化合物的制备方法
CN108658802A (zh) 一种手性双[n,o]环钯配合物及其合成方法
CN114177942B (zh) 一种用于醛与丙二腈Knoevenagel缩合反应的催化剂及制备方法
CN113773250B (zh) 一种5-氰基-8-酰氨基喹啉类化合物及其制备方法
CN115155658B (zh) 一类基于vapol合成硒硫类化合物的合成方法
CN115286553B (zh) 一种吲哚化合物的制备方法
CN115784895B (zh) 一种芳基硝基化合物非金属还原制备芳胺化合物的方法
CN107513079B (zh) 一种2,6-二氨基吡啶缩邻羧基苯甲醛双希夫碱钴配合物的制备方法
CN108148054B (zh) 一种吡啶基桥联手性噁唑啉化合物及其合成方法
RU2645680C1 (ru) Дихлорид ди(фенилацетонитрил) палладия и способ его получения
CN115197124A (zh) 碘化铵催化下基于α,β-不饱和肟酯合成多取代吡啶衍生物的方法
JP3505569B2 (ja) α−(シリルメチル)ボロンエノラート及びその製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant